Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AUR300
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Aurinia Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases
Details : AUR300, was secured through a global licensing and research agreement with Riptide Bioscience Inc. (Riptide), a private company. AUR300 is a novel peptide therapeutic that modulates M2 macrophages (a type of white blood cells) via the macrophage mannose ...
Brand Name : AUR300
Molecule Type : Peptide
Upfront Cash : $6.0 million
August 17, 2021
Lead Product(s) : AUR300
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Aurinia Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : RP-182,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Riptide Bioscience Announces Discovery of Novel Immune Checkpoint
Details : RP-182, administered in combination with gemcitabine, produced the best results ever shown in NCI’s KRAS-p16 pancreatic cancer model.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 13, 2020
Lead Product(s) : RP-182,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?